Clopidogrel BMS

Procedural steps taken and scientific information after the authorisation

MAJOR CHANGES[1]

No	Scope	Opinion issued on	Commission Decision Issued/ amended on	Product Information affected[2]	Summary
II/0008	Update of Summary of Product Characteristics, Labelling and Package Leaflet Update of SPC sections 4.2 "Posology and method of administration", 4.4 "Special warnings and precautions for use", 4.5 "Interaction with other medicinal products and other forms of interaction", 5.1 "Pharmacodynamic properties" and 5.2 "Pharmacokinetic properties" to include information on the clopidogrel metabolism pathway, the role of CYP2C19 genetic polymorphism on clopidogrel variability of response, and the potential interaction between clopidogrel and CYP2C19 inhibitors including some proton pump inhibitors, further to the CHMP recommendations taken during the April and May 2009 CHMP meetings. The pharmaceutical form and contents section in the Labelling has also been updated.	23/07/2009	13/08/2009	SPC, Labelling, PL	In March 2009 a publication from JAMA reporting on a large epidemiological study that claimed patients treated simultaneously with clopidrogel and Proton Pump Inhibitors PPI had worse cardiovascular outcomes than those not exposed to PPI was discussed by the PhVWP and CHMP. The CHMP reviewed the evidence pertaining to the drug-drug interaction between clopidrogel and PPIs and analysed this evidence, critical in terms of its methodological and clinical value. Following CHMP recommendations, , the MAH submit a variation to update the sections 4.2, 4.4, 4.5, 5.1 and 5.2 of the SPC (and the corresponding sections of the Package Leaflet) to include available information on this topic. The pharmaceutical form and contents section in the Labelling has also been updated.
II/0003	Change(s) to shelf-life or storage conditions The Marketing Authorisation Holder applied to change the storage conditions of the 75 mg film-coated tablets packed in the PVC/PVDC/Alu blisters from "No special	18/12/2008	13/02/2009	SPC, Labelling, PL	

[1] Major changes e.g. Type II variations, Annex II applications, Renewals and Annual Reassessments
[2] SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet)

No	Scope	Opinion issued on	Commission Decision Issued/ amended on	Product Information affected[2]	Summary
	storage conditions" to "Store below 30°C".				

MINOR CHANGES[3]

No	Scope	Product Information affected[2]	Date[4]
IB/0017	12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec. 13_b_Change in test proc. for active substance - other changes (replacement/addition)		10/11/2009
IB/0015	12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec. 13_b_Change in test proc. for active substance - other changes (replacement/addition)		10/11/2009
IB/0016	13_b_Change in test proc. for active substance - other changes (replacement/addition)		06/11/2009
N/0012	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	PL	26/10/2009
IA/0013	12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening of spec.		21/10/2009
IB/0011	10_Minor change in the manufacturing process of the active substance		11/08/2009
IB/0010	10_Minor change in the manufacturing process of the active substance		10/08/2009
IB/0009	10_Minor change in the manufacturing process of the active substance		10/08/2009
IB/0007	14_a_Change in manuf. of active substance without Ph. Eur. certificate - change in manuf. site		22/01/2009
IB/0006	41_a_02_Change in pack size - change in no. of units outside range of appr. pack size	SPC, Labelling, PL	30/10/2008
IB/0005	41_a_02_Change in pack size - change in no. of units outside range of appr. pack size	SPC, Labelling, PL	30/10/2008
IB/0004	42_a_01_Change in shelf-life of finished product - as packaged for sale	SPC	30/10/2008
IB/0002	10_Minor change in the manufacturing process of the active substance		11/08/2008
IB/0001	10_Minor change in the manufacturing process of the active substance		11/08/2008

[3] Minor changes e.g. Type I variations and Notifications
[4] Date of entry into force of the change